Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients in smoking cessation programs and other settings.

"We offer both serum and urine nicotine and metabolite testing options," Dr. Jannetto says.

The serum test quantifies nicotine and its cotinine metabolite, which has a much longer half-life. The urine test (Test ID: NICOU) quantifies nicotine and cotinine as well as another metabolite, nornicotine, and anabasine, an alkaloid found in tobacco plants.

Quantifying these substances while patients are using tobacco helps tailor nicotine replacement doses early in nicotine cessation treatment. Random nicotine testing can also monitor patient compliance. In addition, testing can check compliance with nicotine-use cessation before anesthesia and be part of initial insurance policy assessments.

Listen to learn more about Mayo Clinic Laboratories' nicotine testing.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

NICOU   | Nicotine and Metabolites, Random, Urine

NCSRY   | Nicotine Survey, Serum

ADMPU   | Addiction Medicine Profile with Reflex, 22 Drug Classes, High Resolution Mass Spectrometry and Immunoassay Screen, Random, Urine

The latest

Assay provides quick diagnosis of VEXAS syndrome: David S. Viswanatha, M.D.

April 30, 2024

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.

April 23, 2024

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

April 16, 2024

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

View MoreView Less